Abstract
This account comprehensively reviews the recent advancements in the development of
mechanistic target of rapamycin (mTOR) inhibitors targeting non-small-cell lung cancer
(NSCLC), focusing on their mechanisms, efficacy, and clinical trial statuses. Key
small molecules such as RM-018 and RMC-4998 highlight novel approaches in targeting
the KRASG12C mutation, offering enhanced potency compared to earlier inhibitors. Traditional
and plant-derived compounds, including Fuzi alkaloids, salvianolic acid, and ononin,
demonstrate promising antitumor activities through diverse pathways, such as the PI3K/AKT/mTOR
signaling axis. Combination therapies targeting dual pathways show synergistic effects,
improving treatment efficacy. The role of personalized medicine, driven by genetic
profiling and pathway-specific inhibitors, is emphasized as a transformative approach
in NSCLC management. These findings highlight the potential of mTOR-targeting agents
as a cornerstone in advancing NSCLC therapies.
1 Introduction
2 Small-Molecule mTOR Inhibitors
3 mTOR Inhibitors in Clinical Trials
4 Conclusion and Future Directions
Key words
mTOR - small molecules - rapalogs - clinical trials - cancer
